- Home
- OPCH vs OGN Comparison
OPCH vs OGN Comparison
Compare OPCH & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OPCH | OGN |
|---|---|---|
| Founded | N/A | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 1.8B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | OPCH | OGN |
|---|---|---|
| Price | $32.37 | $6.83 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 10 | 5 |
| Target Price | ★ $36.30 | $14.10 |
| AVG Volume (30 Days) | 2.1M | ★ 4.8M |
| Earning Date | 10-30-2025 | 11-10-2025 |
| Dividend Yield | N/A | ★ 1.17% |
| EPS Growth | ★ 6.77 | N/A |
| EPS | 1.27 | ★ 1.91 |
| Revenue | $5,530,491,000.00 | ★ $6,301,000,000.00 |
| Revenue This Year | $15.08 | N/A |
| Revenue Next Year | $7.44 | N/A |
| P/E Ratio | $25.60 | ★ $3.57 |
| Revenue Growth | ★ 15.79 | N/A |
| 52 Week Low | $22.29 | $6.18 |
| 52 Week High | $35.53 | $17.23 |
Technical Indicators
Market Signals| Indicator | OPCH | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 61.91 | 38.66 |
| Support Level | $29.43 | $6.82 |
| Resistance Level | $33.69 | $7.14 |
| Average True Range (ATR) | 0.92 | 0.27 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 68.77 | 8.20 |
Price Performance
Historical ComparisonAbout OPCH Option Care Health Inc.
Option Care Health Inc is the provider of home and alternate-site infusion services. It provides treatment for bleeding disorders, neurological disorders, heart failure, anti-infectives, and chronic inflammatory disorders among others.
About OGN Organon & Co.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.